

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number  
**WO 02/17885 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 9/20**,  
31/7048

(21) International Application Number: **PCT/IB01/01564**

(22) International Filing Date: 29 August 2001 (29.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
778/DEL/2000 29 August 2000 (29.08.2000) IN

(71) Applicant (for all designated States except US): **RAN-  
BAXY LABORATORIES LIMITED** [IN/IN]; 19, Nehru  
Place, New Delhi 110 019 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RAMPAL, Ashok**  
[IN/IN]; 14, Sewa Nagar, Ram Tirath Road, Amritsar  
143001, Punjab (IN). **RAGHUVANSHI, Rajeev, S.**  
[IN/IN]; Flat No. 8131, Block: D-8, Vasant Kunj, New  
Delhi 110 070 (IN). **KUMAR, Manoj** [IN/IN]; c/o Mr.  
O.P. Ahuja, House No. 157, Sector-16A, Faridabad  
122001, Haryana (IN).

(74) Common Representative: **DESHMUKH, Jayadeep, R.;**  
Ranbaxy Laboratories Limited, 600 College Road East,  
Suite 2100, Princeton, NJ 08540 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

**Declaration under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL,  
SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),  
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG)

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 02/17885 A2

(54) Title: CONTROLLED RELEASE FORMULATION OF ERYTHROMYCIN OR A DERIVATIVE THEREOF

(57) Abstract: The present invention relates to a controlled release pharmaceutical composition, suitable for once daily adminis-  
tration, of erythromycin or a derivative thereof and the process for its preparation. More preferably, it relates to a controlled release  
pharmaceutical composition of clarithromycin suitable for once daily administration.

## **CONTROLLED RELEASE FORMULATION OF ERYTHROMYCIN OR A DERIVATIVE THEREOF**

### **FIELD OF THE INVENTION**

5       The present invention relates to a controlled release pharmaceutical composition, suitable for once daily administration, of erythromycin or a derivative thereof and the process for its preparation. More preferably, it relates to a controlled release pharmaceutical composition of clarithromycin suitable for once daily administration.

### **BACKGROUND OF THE INVENTION**

10       It is well known to those skilled in the art that the blood levels of drugs need to be maintained above a minimum effective level and below its minimum toxic level in order to obtain the desired therapeutic effects and to minimize side effects. Unfortunately, the pharmacokinetic properties (absorption, elimination and metabolism) of most drugs are such that they  
15       need to be administered three to four times a day. This kind of a dosing regimen is very inconvenient and leads to reduction in patient compliance. Reduction of dosing regimen from three times a day (tid) to twice daily (bid) to once a day results in increased convenience and comfort and therefore increased patient compliance. Controlled release formulations which are  
20       effective in maintaining the therapeutic blood levels over extended periods of time result in optimal therapy. They not only reduce the frequency of dosing, but they also reduce the severity and frequency of side effects, as they maintain substantially constant blood levels and avoid the fluctuations

associated with the conventional immediate release formulations administered three to four times a day.

Erythromycin and its derivatives are known for their antibacterial activity against a number of organisms and are typically administered at least  
5 two to three times a day as immediate release compositions. In particular, the 6-O-methoxyerythromycin A (clarithromycin) which has been disclosed in U.S. Patent No. 4,331,803 has to be administered at least twice daily for optimal effect.

Clarithromycin presents a peculiar problem for the formulator as it has  
10 greater solubility in the upper part of the gastrointestinal tract (GIT) but is very unstable at the acidic pH conditions in the GIT, and while its stability is good at alkaline pH of the large intestine (pH 6.0 to 8.0), its solubility is poor there. This results in poor bioavailability of clarithromycin.

U.S. Patent No. 5,705,190 assigned to Abbott Laboratories describes  
15 controlled release compositions for such poorly soluble basic drugs comprising a water soluble alginate salt, a complex salt of alginic acid and an organic carboxylic acid to facilitate dissolution of the basic drug at a higher pH. As desired, the formulations described in the specification of this patent have an area under the plasma concentration - time curve (AUC) and  
20 minimum plasma concentration (Cmin) values which are substantially similar to those obtained by the immediate release tablets given twice daily. The maximum plasma concentration (Cmax) values, however, did not show the

desired reduction and were similar to those for immediate release formulations.

Further, the total tablet weight of each tablet containing 500mg drug as described in the examples of this invention is more than 900 mg, as  
5 substantial amounts of polymers are required for controlling the rate of drug release. A single tablet containing 1000mg drug, when made according to this invention would weigh at least 1800mg. This would be unacceptably large for human consumption, and two tablets of 500mg strength each would be required for administering the daily adult dose of 1000mg clarithromycin.

10 U.S. Patent No. 6,010,718 also assigned to Abbott describes an extended release pharmaceutical dosage form for clarithromycin, using from about 5 to about 50% by weight of a pharmaceutically acceptable polymer. The formulations described in this patent result not only in AUC and Cmin values similar to that of immediate release formulations administered twice  
15 daily, but also result in statistically significantly lower Cmax values. The total weight of the formulation as exemplified in this invention is close to 1000 mg for a tablet containing 500 mg drug. Once again, a single tablet would be unacceptably large at 2000mg thus necessitating the administration of two tablets of 500mg strength each for delivering the daily dose of 1000mg  
20 clarithromycin.

U.S. Patent No. 4,808,411 assigned to Abbott Laboratories claims a composition comprising from about 25% to about 95% of erythromycin A or a derivative thereof, and from about 5% to about 75% of a carbomer. The

specification of this patent describes that the compositions made according to this invention provide palatable dosages of antibiotics. The pharmacokinetic properties, however, are not suitable for extended release and are substantially equivalent to commercially available immediate-release tablet and capsule formulations.

Accordingly, none of the oral controlled drug delivery systems heretofore described is completely satisfactory.

Our U.S. Patent No. 6,261,601 describes a dosage form which is retained in the stomach for extended period of time and can deliver drugs to the stomach at a controlled rate. This delivery system is particularly useful for drugs which are stable in the acidic milieu of the stomach and which have a window of drug absorption from upper parts of gastro-intestinal in the stomach. The dosage form described in this application utilizes a unique combination of gel forming polymers, viscosity enhancing agents, hydrophilic polymers and gas generating agent. This application has however not explored the use of such systems for controlling the release of acid degradable drugs.

### **SUMMARY OF THE INVENTION**

It is an object of the present invention to provide a controlled release formulation for erythromycin or derivatives thereof that can deliver a daily dose of the drug in a single unit dosage form and wherein the rate controlling polymers are present at very small amounts of from about 0.1 to 4.0% w/w of the total weight of the dosage form, and wherein the delivery system

maintains its physical integrity and a monolithic form when contacted with an aqueous media.

It is a further object of the present invention to provide a controlled release formulation for once daily administration of erythromycin or derivatives thereof, that contains a high dose medicament and is of an acceptable size which is convenient for oral administration. The use of small amounts of rate controlling polymers ensures that total weight of the dosage form is low and a single dosage unit is sufficient to provide the therapeutic dosage of the drug compared to two units which need to be administered if the teachings of the prior art are to be followed. The present invention provides obvious benefits with respect to better patient convenience and therefore patient compliance.

The present invention provides a controlled release formulation of erythromycin or derivatives thereof for once daily administration comprising an effective amount of the drug and about 0.1% w/w to about 4.0% w/w of one or more pharmaceutically acceptable rate controlling polymers.

More preferably, the present invention provides a controlled release formulation of clarithromycin for once daily administration comprising an effective amount of drug and from about 0.1% w/w to about 4.0% w/w of one or more pharmaceutically acceptable rate controlling polymers.

The present invention also provides a process for the preparation of a controlled release formulation of erythromycin or derivatives thereof for once daily administration comprising mixing a pharmaceutically effective amount of

the drug with about 0.1% w/w to about 4.0% w/w of one or more pharmaceutically acceptable rate controlling polymers.

Clarithromycin used in accordance with the present invention comprises about 10% to about 90% w/w of the total formulation weight. More preferably, it constitutes about 50% to about 90% w/w of the formulation. The particle size of the drug may be reduced by techniques conventionally known in the art such as milling, pulverization, sieving, *etc.*

The pharmaceutically acceptable rate controlling polymers used in accordance with the present invention comprises of carbohydrate gums, polyuronic acid salts, cellulose ethers, acrylic acid polymers and mixtures thereof.

Carbohydrate gums may be selected from amongst xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum, locust bean gum, sclero gum and the like. These gums upon contact with the gastro intestinal fluid form a viscous gel and help in maintaining the tablet integrity and sustaining the release of the drug even when used in very small amounts. In preferred embodiments of this invention, the carbohydrate gum used is "xanthan gum" which is extraordinarily enzymatically resistant.

Examples of polyuronic acid salts that may be used in the present invention include alkali metal salts of alginic acid, alkali metal salts of pectic acid and mixtures thereof. In preferred embodiments of this invention, the water soluble salt of polyuronic acid is a salt of alginic acid, which is a mixture of two polyuronic acids, namely mannuoronic acid and gulucronic acid.

Examples of alkali metal salts of alginic acid that may be used in the present invention include sodium alginate, potassium alginate, ammonium alginate, and the like. Importantly, when the pharmaceutical composition contains a water soluble salt of one or more polyuronic acids preferably a salt of alginic acid, it should be free of calcium ions.

The cellulose ethers used in accordance with the present invention include hydroxypropyl methylcellulose, hydroxypropyl cellulose, and the like. The polyacrylic acid polymers used may be such as is available under the brand name Carbopol (B.F. Goodrich, USA).

In addition to the rate controlling polymers, the composition may additionally contain about 6 to 50% w/w of other pharmaceutically acceptable excipients such as gas generating components, swelling agents, lubricants and fillers.

The gas generating components may constitute a single substance known to produce gas upon contact with gastric fluid, or may consist of a gas generating couple. Examples of the gas generating component that may be used in the present invention include carbonates, such as calcium carbonate or sodium glycine carbonate, bicarbonates, such as sodium hydrogen carbonate or potassium hydrogen carbonate, sulfites, such as sodium sulfite, sodium bisulfite or sodium metabisulfite, and the like. The gas generating component interacts with an acid source triggered by contact with water or simply gastric fluid to generate gas. These salts can be used alone or in combination with an acid source as a couple. Examples of organic acids that



may be used as an acid source include citric acid or its salts such as sodium or calcium citrate, malic acid, tartaric acid, succinic acid, fumaric acid, maleic acid or their salts, ascorbic acid and its salts such as sodium or calcium ascorbate. The organic acid salts include mono or bialkali salts of organic acids having one or more than one carboxylic groups. Most preferably the gas generating agent is sodium bicarbonate. The gas generating components may be present at 5-45% w/w of the total weight of the formulation.

The swelling agent is one which is capable of swelling to greater than its original volume when coming into contact with an aqueous fluid such as the gastrointestinal fluid. Examples of such swelling agents that may be used in the present invention include cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose sodium, sodium starch glycolate, and the like. This class of compounds is also known as superdisintegrants and is present in an amount of from about 5 to about 25% w/w of the formulation. More preferably, it is present in an amount from about 10% to about 20% w/w of the total weight of the formulation.

The composition according to the present invention also contains pharmaceutically acceptable lubricants such as those selected from amongst talc, calcium stearate, magnesium stearate, polyethylene glycols, silicon dioxide, sodium lauryl sulfate, sodium stearyl fumarate and mixtures thereof.

The composition according to the present invention also contains fillers selected from amongst those conventionally used in the art such as lactose,

starches, glucose, sucrose, mannitol, silicic acid and mixtures thereof. Fillers are present at about 5% to about 15% w/w of the formulation.

According to the present invention, the pharmaceutical composition can incorporate a high dose medicament. The amount of drug used in the composition varies from about 100 to 1000 mg and the total weight of the tablet does not exceed more than 1500 mg. The tablets made according to the present invention are unique as they carry a very high payload of the drug and use very small amounts of polymers for controlling the drug release while at the same time maintaining the integrity of the tablet for extended periods of time.

The composition according to the present invention may be formulated as a capsule or tablet. Most preferably, the composition is a tablet. The tablet formulation can be prepared by wet granulation, dry granulation, direct compression or by any other technique known in the pharmaceutical art. The tablet made according to the present invention may optionally be coated with a thin layer of a rapidly dissolving water soluble polymer or pharmaceutical excipient(s).

#### **DETAILED DESCRIPTION OF THE INVENTION**

The examples given herein further illustrate the invention and are not intended to limit the scope of the invention.

**EXAMPLE 1****Table 1.1**

<b>Ingredients</b>	<b>mg/tab</b>	<b>Percent w/w of tablet weight</b>
Clarithromycin equivalent to	1000.0	81.0
Sodium Alginate (LVCR)	12.5	1.0
Xanthan Gum	37.5	3.0
Cross-linked polyvinylpyrrolidone (CL-PVP)	125.0	10.1
Magnesium Stearate	12.5	1.0
Talc	20.0	1.6
Sodium stearyl fumarate	20.0	1.6
Aerosil 200	8.0	0.70
Purified water	Qs	qs
Total weight	1235.5	100.0

Clarithromycin, sodium alginate, xanthan gum and CL-PVP were  
 5 sieved through a British Standard Sieve (BSS) 44 mesh sieve and blended  
 together followed by granulation with water. The granules were dried in a fluid  
 bed drier at 60°C for 20 minutes. The dried granules were sifted through a  
 BSS 16 mesh sieve. The granules obtained were lubricated with the  
 remaining ingredients namely talc, magnesium stearate, sodium stearyl  
 10 fumarate and aerosil 200 and compressed to tablets.

The drug release from the tablets was monitored at pH 5.0 acetate  
 buffer in USP apparatus I at 100 rpm and the results obtained are given in  
 Table 1.2.

Table 1.2

Time (h)	Cumulative Percent drug released
1	19.0
2	27.0
4	40.0
6	45.0
8	51.0
10	55.0

The drug release was extended to more than 10 hours despite the use of only 4% w/w of the total rate controlling polymers indicating the efficacy of control. Release of only 55% of the drug in ten hours, was however unacceptably slow. The formulation was therefore modified to include a gas generating component to accelerate the rate of drug release as described in the next experiment.

## EXAMPLE 2

Table 2.1

Ingredients	Mg/tab	Percent w/w of tablet weight
Clarithromycin equivalent to	1000.0	75.0
Sodium bicarbonate	100.0	7.5
Sodium Alginate (LVCR)	50.0	3.7
Cross-linked polyvinylpyrrolidone (CL-PVP)	125.0	9.40
Magnesium Stearate	12.5	0.90
Talc	20.0	1.5
Sodium stearyl fumarate	20.0	1.5
Aerosil 200	8.0	0.6
Purified Water	Qs	qs
Total weight	1335.5	100.0

Tablets were made by the same process as described in Example 1 and evaluated for drug release (Table 2.2).

**Table 2.2**

**Percent drug released in pH 5.0 acetate buffer  
in USP apparatus I at 100 rpm.**

<b>Time (h)</b>	<b>Cumulative Percent drug released</b>
1	21.0
2	30.0
4	48.0
6	78.0
8	85.0
10	87.0

**EXAMPLE 3**

**Table 3.1**

<b>Ingredients</b>	<b>mg/tab</b>	<b>Percent w/w of tablet weight</b>
Clarithromycin equivalent to	1000.0	75.0
Hydroxypropyl methylcellulose (HPMC K100 MCR)	50.0	3.7
Sodium bicarbonate	100.0	7.5
Cross-linked polyvinylpyrrolidone (CL-PVP)	125.0	9.4
Magnesium Stearate	12.5	0.9
Talc	20.0	1.5
Sodium Stearyl Fumarate	20.0	1.5
Aerosil 200	8.0	0.6
Purified water	Qs	qs
Total weight	1335.5	100.0

Tablets were made following the same process that described in Example 1, and subjected to dissolution testing in USP apparatus I, at 100 rpm in pH 5.0 acetate buffer. The dissolution profile is given in Table 3.2.

**Table 3.2**

<b>Time (h)</b>	<b>Cumulative Percent drug released</b>
1	25.0
2	36.0
4	54.0
6	64.0
8	73.0
10	76.0

5

**EXAMPLE 4****Table 4.1**

<b>Ingredients</b>	<b>mg/tab</b>	<b>Percent w/w of tablet weight</b>
Clarithromycin equivalent to	1000.0	84.3
Hydroxypropyl methylcellulose (HPMC K100MCR)	12.5	1.1
Sodium bicarbonate	100.0	8.4
Magnesium Stearate	12.5	1.1
Talc	10.0	0.8
Sodium Stearyl fumarate	20.0	1.7
Aerosil 200	5.0	0.4
Purified water	qs	qs
Total weight	1185.5	100.0

The tablets were made as described in Example 1. Only 1% HPMC was used as the rate controlling polymer. Tablets made according to the present example containing only 1% of rate controlling polymer were not only able to maintain their monolithic form, but were also capable of controlling the

10

release of clarithromycin over an extended period of time as shown in Table 4.2.

Table 4.2

Time (h)	Percent drug released
1	7.0
2	12.0
4	16.0
6	24.0
8	53.0

5

## EXAMPLE 5

Table 5.1

Ingredients	Mg/tab	Percent w/w of tablet weight
Clarithromycin equivalent to	1019.0	80.3
Sodium alginate (LVCR)	12.5	1.1
Xanthan Gum	37.5	3.01
Sodium bicarbonate	100.0	8.0
Magnesium Stearate	20.0	1.6
Talc	20.0	1.6
Sodium stearyl fumarate	30.0	2.4
Aerosil 200	5.0	0.4
Purified water	qs	qs
Total weight	1244.8	100.0

Tablets were made as described in Example 1 and Table 5.2 gives the dissolution profile of these tablets in pH 5.0 acetate buffer, USP apparatus I at 100 rpm.

10

**Table 5.2**

<b>Time (h)</b>	<b>Cumulative Percent drug released</b>
1	5
2	13
4	29
6	48
8	62
10	70

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.



**CLAIMS :**

1. A controlled release formulation of erythromycin A or a derivatives thereof, suitable for once daily administration, comprising a pharmaceutically effective amount of erythromycin and from about 0.1% to about 4% w/w of one or more pharmaceutically acceptable rate controlling polymers.
2. A controlled release formulation as described in claim 1, wherein the erythromycin A derivative is clarithromycin.
3. A controlled release formulation as described in claim 1 wherein erythromycin A or its derivative comprises about 10% w/w to about 90% w/w of the total tablet weight.
4. A controlled release formulation as described in claim 3 wherein erythromycin A or its derivative preferably comprises about 50% w/w to about 90% w/w of the total tablet weight.
5. A controlled release formulation described in claim 1 wherein the pharmaceutically acceptable rate controlling polymer comprises of carbohydrate gum, polyuronic acid salt, cellulose ether, acrylic acid polymer, and mixtures thereof.
6. A controlled release formulation as described in claim 5 wherein the carbohydrate gum is selected from the group consisting of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum, locust bean gum, sclero gum, and mixtures thereof.

7. A controlled release formulation as described in claim 5 wherein the polyuronic acid salt is selected from the group consisting of alkali metal salts of pectic acid, alkali metal salts of alginic acid, and mixtures thereof.
8. A controlled release formulation as described in claim 7 wherein the polyuronic acid salt is preferably sodium alginate.
9. A controlled release formulation as described in claim 5 wherein the cellulose ether are selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropylcellulose, and mixtures thereof.
10. A controlled release formulation as described in claim 5 wherein the acrylic acid polymer is carbopol.
11. A controlled release formulation as described in the preceding claims wherein the formulation may additionally contain other pharmaceutically acceptable excipients such as gas generating components, swelling agents, lubricants and fillers.
12. A controlled release formulation as described in claim 11, wherein the gas generating component is selected from the group consisting of sodium bicarbonate, calcium carbonate, sodium carbonate and mixtures thereof either alone or in combination with an organic acid as a couple.
13. A controlled release formulation as described in claim 12, wherein the organic acid is selected from the group comprising citric acid, malic

acid, tartaric acid, succinic acid, fumaric acid, maleic acid, ascorbic acid and their salts.

14. A controlled release formulation as described in claim 12 wherein the gas generating component is preferably sodium bicarbonate.
15. A controlled release formulation as described in claim 12, wherein the gas generating agent comprises about 5% w/w to about 15% w/w of the tablet.
16. A controlled release formulation as described in claim 11 wherein the swelling agent is selected from the group consisting of cross-linked polyvinyl pyrrolidone, cross-linked carboxymethylcellulose sodium, sodium starch glycolate and mixtures thereof.
17. A controlled release formulation as described in claim 16 wherein the swelling agent comprises about 5% w/w to about 25% w/w of the tablet.
18. A controlled release formulation as described in claim 11 wherein the fillers are selected from the group consisting of monosaccharides, disaccharides and polysaccharides.
19. A controlled release formulation as described in claim 18 wherein the fillers comprises about 5% w/w to about 15% w/w of the tablet.
20. A controlled release formulation as described in claims 11 wherein the lubricants are selected from amongst the group consisting of talc,

calcium stearate, magnesium stearate, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulfate and mixtures thereof.

21. A controlled release formulation as described in the preceding claims wherein the formulation may be a tablet or a capsule.
22. A controlled release formulation as described in claim 21 wherein the formulation is a tablet.
23. A controlled release formulation as described in claim 22 wherein the tablet is optionally coated.
24. A monolithic controlled release formulation of clarithromycin comprising 100-1000 mg of clarithromycin, wherein the total weight of the dosage unit is not more than 1500 mg.
25. A process for the preparation of a controlled release formulation of erythromycin A or a derivative thereof suitable for once daily administration comprising mixing a pharmaceutically effective amount of erythromycin or a derivative thereof with about 0.1% to about 4% w/w of one or more pharmaceutically acceptable rate controlling polymers.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number  
**WO 02/017885 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 9/20**,  
31/7048

SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW.

(21) International Application Number: PCT/IB01/01564

(22) International Filing Date: 29 August 2001 (29.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
778/DEL/2000 29 August 2000 (29.08.2000) IN

(71) Applicant (for all designated States except US): **RAN-  
BAXY LABORATORIES LIMITED** [IN/IN]; 19, Nehru  
Place, New Delhi 110 019 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RAMPAL, Ashok**  
[IN/IN]; 14, Sewa Nagar, Ram Tirath Road, Amritsar  
143001, Punjab (IN). **RAGHUVANSHI, Rajeev, S.**  
[IN/IN]; Flat No. 8131, Block: D-8, Vasant Kunj, New  
Delhi 110 070 (IN). **KUMAR, Manoj** [IN/IN]; c/o Mr.  
O.P. Ahuja, House No. 157, Sector-16A, Faridabad  
122001, Haryana (IN).

(74) Common Representative: **DESHMUKH, Jayadeep, R.**;  
Ranbaxy Laboratories Limited, 600 College Road East,  
Suite 2100, Princeton, NJ 08540 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

**Declaration under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL,  
SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),  
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG)

**Published:**

— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
6 September 2002

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: CONTROLLED RELEASE FORMULATION OF ERYTHROMYCIN OR A DERIVATIVE THEREOF

(57) Abstract: The present invention relates to a controlled release pharmaceutical composition, suitable for once daily adminis-  
tration, of erythromycin or a derivative thereof and the process for its preparation. More preferably, it relates to a controlled release  
pharmaceutical composition of clarithromycin suitable for once daily administration.

WO 02/017885 A3

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 01/01564

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/20 A61K31/7048

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 15198 A (STANIFORTH JOHN H ;SEN HIMADRI (IN); TALWAR NARESH (IN); RANBAXY L) 23 March 2000 (2000-03-23) cited in the application page 1, paragraph 1 page 6, line 18 -page 10, line 21 page 13, line 11 -page 22, line 18; examples 1-3 ---	1-23,25
X	US 5 009 897 A (BRINKER DALE R ET AL) 23 April 1991 (1991-04-23)  column 1, line 31 - line 40 column 2, line 30 -column 3, line 3; example 3 --- -/--	1,3-6,9, 11, 21-23,25



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

26 June 2002

Date of mailing of the international search report

05/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

## INTERNATIONAL SEARCH REPORT

In.....onal Application No

PCT/IB 01/01564

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 076 804 A (SINGISER ROBERT E ET AL) 28 February 1978 (1978-02-28)  column 4, line 42 - line 61; example 1 column 1, line 21 - line 23 column 5, line 11 - line 12 ---	1,3,5,6, 11,16, 18, 21-23,25
X	US 4 176 180 A (BARBIER PIERRE) 27 November 1979 (1979-11-27)  column 4, line 45 - line 56; example 2 ---	1,3-5, 11,18, 20-23,25
X	WO 00 48607 A (LEK TOVARNA FARMACEVTSKIH ;MOHAR MILOJKA (SI); REBI & CCARON (SI);) 24 August 2000 (2000-08-24) page 2, line 4 - line 8; claims 1,6,7,10,13; examples 1-5 ---	24
X	US 6 010 718 A (GUSTAVSON LINDA E ET AL) 4 January 2000 (2000-01-04) cited in the application claim 1; example 1 ---	24
X	WO 97 22335 A (ABBOTT LAB) 26 June 1997 (1997-06-26) cited in the application claims 1-3; examples 1,2 -----	24

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 01/01564

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0015198	A	23-03-2000	AU 1779499 A	03-04-2000
			BG 105339 A	30-11-2001
			BR 9913696 A	09-10-2001
			CN 1325299 T	05-12-2001
			CZ 20010901 A3	15-08-2001
			EP 1107741 A1	20-06-2001
			HR 20010187 A1	30-04-2002
			WO 0015198 A1	23-03-2000
			NO 20011276 A	10-05-2001
			PL 346798 A1	25-02-2002
			SK 3472001 A3	08-10-2001
			TR 200100731 T2	21-06-2001
			ZA 9905839 A	28-03-2000
US 5009897	A	23-04-1991	AT 82497 T	15-12-1992
			AU 3656189 A	04-01-1990
			CA 1335258 A1	18-04-1995
			DE 68903536 D1	24-12-1992
			DE 68903536 T2	22-04-1993
			EP 0347748 A2	27-12-1989
			ES 2052816 T3	16-07-1994
			GR 3006537 T3	30-06-1993
			IE 63242 B	05-04-1995
			JP 2045418 A	15-02-1990
			JP 2862567 B2	03-03-1999
			US 5169642 A	08-12-1992
			US 5268182 A	07-12-1993
US 4076804	A	28-02-1978	AU 3172277 A	28-06-1979
			BE 862642 A1	04-07-1978
			DE 2758942 A1	05-07-1979
			FR 2413090 A1	27-07-1979
			JP 54086605 A	10-07-1979
US 4176180	A	27-11-1979	GB 1577196 A	22-10-1980
			AU 519743 B2	17-12-1981
			AU 3683778 A	06-12-1979
			BE 867396 A1	24-11-1978
			CA 1119097 A1	02-03-1982
			CH 631623 A5	31-08-1982
			DE 2823655 A1	07-12-1978
			HK 40582 A	24-09-1982
			IE 46984 B1	16-11-1983
			IT 1156786 B	04-02-1987
			JP 1075120 C	30-11-1981
			JP 54005047 A	16-01-1979
			JP 56020285 B	13-05-1981
			NL 7805897 A ,B,	05-12-1978
			NZ 187401 A	29-05-1981
			SE 443923 B	17-03-1986
			SE 7806441 A	04-12-1978
			ZA 7803131 A	27-06-1979
WO 0048607	A	24-08-2000	SI 20150 A	31-08-2000
			AU 2704900 A	04-09-2000
			BG 105914 A	31-05-2002
			CZ 20012964 A3	16-01-2002
			EP 1150686 A1	07-11-2001



INTERNATIONAL SEARCH REPORT  
Information on patent family members

International Application No

PCT/IB 01/01564

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0048607 A		WO 0048607 A1 TR 200102396 T2	24-08-2000 21-01-2002
US 6010718 A	04-01-2000	AU 737324 B2 AU 6346398 A BG 103862 A BR 9807974 A CA 2325541 A1 EP 0973527 A1 HU 0001382 A2 JP 2001524955 T NO 994946 A NZ 337120 A PL 336142 A1 SK 138099 A3 TR 9902149 T2 WO 9846239 A1 ZA 9802916 A	16-08-2001 11-11-1998 31-07-2000 08-03-2000 22-10-1998 26-01-2000 28-09-2000 04-12-2001 11-10-1999 27-04-2001 05-06-2000 10-04-2000 21-12-1999 22-10-1998 09-10-1998
WO 9722335 A	26-06-1997	US 5705190 A AT 170744 T AU 701268 B2 AU 1025297 A CA 2209714 A1 CZ 9702212 A3 DE 69600620 D1 DE 69600620 T2 DK 799028 T3 EP 0799028 A1 ES 2122810 T3 HU 9800516 A2 JP 11513406 T NZ 323332 A PL 321363 A1 RU 2142793 C1 TR 9800777 T2 TW 429154 B WO 9722335 A1 WO 9856357 A1 ZA 9610110 A	06-01-1998 15-09-1998 21-01-1999 14-07-1997 26-06-1997 17-12-1997 15-10-1998 06-05-1999 07-06-1999 08-10-1997 16-12-1998 28-08-1998 16-11-1999 27-04-1998 08-12-1997 20-12-1999 21-07-1998 11-04-2001 26-06-1997 17-12-1998 18-06-1997

**THIS PAGE BLANK (USPTO)**